1 study found for:    11679149 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
Condition: HIV Infections
Interventions: Drug: Ritonavir;   Biological: gp160 Vaccine (Immuno-AG);   Drug: Stavudine;   Drug: Didanosine

Indicates status has not been verified in more than two years